Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from BONESUPPORT HOLDING AB ( (SE:BONEX) ).
BONESUPPORT announced that the U.S. Centers for Medicare & Medicaid Services has proposed improved Medicare inpatient payments for the use of its CERAMENT G bone graft substitute in treating complex orthopedic infections, including periprosthetic joint infection, fracture-related infections, and diabetes-related bone infections. CMS also plans to introduce more specific procedure and identification codes for CERAMENT G and CERAMENT V, and has proposed New Technology Add-on Payment reimbursement for CERAMENT V from October 1, 2026, contingent on timely FDA De Novo approval, with BONESUPPORT engaging in the public comment process ahead of a final CMS decision expected in late summer 2026.
More about BONESUPPORT HOLDING AB
BONESUPPORT is a Nasdaq Stockholm–listed orthobiologics company that develops and commercializes innovative injectable bio-ceramic bone graft substitutes designed to remodel into patients’ own bone and deliver local drug elution. Its CERAMENT product family targets complex bone injuries and infections, and the Sweden-based company reported net sales of SEK 1,175 million in 2025, reflecting growing global adoption in orthopedic care.
Average Trading Volume: 335,044
Technical Sentiment Signal: Buy
Current Market Cap: SEK15.13B
Find detailed analytics on BONEX stock on TipRanks’ Stock Analysis page.